FINWIRES · TerminalLIVE
FINWIRES

HKG:0867

6 stories mentioning HKG:0867Updated 21d ago

Every FINWIRES story that references HKG:0867, newest first.

Asia

China Medical System Secures Clinical Trial Approval for Macular Degeneration Drug

China Medical System (HKG:0867, SGX:8A8) obtained approval from China's National Medical Products Administration for the clinical trial of the self-developed complement factor B inhibitor CMS-D017 capsules, according to a Wednesday filing with the Singapore Exchange.Under the approval, the pharmaceutical company can now conduct trials to evaluate the drug's safety and efficacy for treating age-related macular degeneration.

HKG:0867SGX:8A8
Asia

InSilico Medicine, CMS Expand Drug Development Partnership

InSilico Medicine (HKG:3696) expanded its collaboration with China Medical System (HKG:0867, SGX:8A8) to jointly develop innovative drugs for central nervous system diseases, according to a Monday filing with the Hong Kong bourse.Under the agreement, InSilico will combine its artificial intelligence drug discovery platform with CMS' research and development capabilities and therapeutic expertise to advance the programs.InSilico said it is eligible to receive milestone payments of up to 1.20 billion yuan, plus royalties based on net sales under the collaboration.

HKG:0867HKG:3696SGX:8A8
Asia

China Medical System Secures Approval for Anti-Rabies Antibody

China Medical System (HKG:0867, SGX:8A8) was granted an approval for its Silevimig Injection, an antibody aimed at providing immunity against rabies, according to a Monday filing with the Singapore Exchange.The approval, which was secured by China's National Medical Products Administration, will now lead the way for manufacturing at scale, with the treatment option available for patients requiring urgent post-exposure management against rabies.

HKG:0867SGX:8A8
Asia

China Medical System Gets China Nod for Rabies Drug Application

China Medical System (HKG:0867, SGX:8A8) obtained approval for the new drug application of Silevimig Injection from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The product is indicated for passive immunization in adults following rabies virus exposure.

HKG:0867SGX:8A8
Asia

China Medical System Gets China Trial Approval for Crohn's, Colitis Drug

China Medical System's (HKG:0867, SGX:8A8) said China's National Medical Products Administration approved clinical trials of its self-developed TYK2 inhibitor CMS-D001 for ulcerative colitis and Crohn's disease, according to a Tuesday Hong Kong bourse filing.The company said CMS-D001 is being developed for inflammatory bowel disease indications, including ulcerative colitis and Crohn's disease, and may also be developed for autoimmune conditions such as systemic lupus erythematosus in the future.

HKG:0867SGX:8A8
Asia

China Medical System Gets China Acceptance for Seasonal Allergic Rhinitis Drug Indication of MG-K10

China Medical System's (HKG:0867, SGX:8A8) new drug application for the seasonal allergic rhinitis indication of MG-K10 was accepted by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The firm holds co-development rights, excluding the indication of atopic dermatitis, and exclusive commercialization rights for the drug.The drug is proposed to treat adult patients with moderate-to-severe seasonal allergic rhinitis whose symptoms are inadequately controlled following treatment with intranasal corticosteroid.

HKG:0867SGX:8A8

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:0867 in your portfolio
WheelAI
WheelAI
Analyze HKG:0867 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:0867